What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Cancer
- Breast cancer
His primary areas of investigation include Internal medicine, Breast cancer, Gynecology, Women's Health Initiative and Cancer.
His Internal medicine study frequently draws connections between adjacent fields such as Oncology.
Rowan T. Chlebowski has researched Breast cancer in several fields, including Prospective cohort study, Surgery and Incidence.
His Gynecology research incorporates elements of Medroxyprogesterone acetate, Estrogen, Mammography, Placebo and Hormone therapy.
His Women's Health Initiative research is multidisciplinary, relying on both Body mass index, Clinical trial, Obstetrics, Physical therapy and Hormone replacement therapy.
His studies in Cancer integrate themes in fields like Lung cancer and Carcinoma.
His most cited work include:
- Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial (3739 citations)
- Design of the Women's Health Initiative clinical trial and observational study (1868 citations)
- Influence of Estrogen Plus Progestin on Breast Cancer and Mammography in Healthy Postmenopausal Women: The Women's Health Initiative Randomized Trial (1564 citations)
What are the main themes of his work throughout his whole career to date?
His primary areas of study are Internal medicine, Breast cancer, Oncology, Women's Health Initiative and Cancer.
The Internal medicine study which covers Endocrinology that intersects with Case-control study.
The Breast cancer study combines topics in areas such as Gynecology, Incidence and Risk factor.
Rowan T. Chlebowski combines subjects such as Aromatase inhibitor, Aromatase, Endometrial cancer and Adjuvant therapy with his study of Oncology.
His Women's Health Initiative study incorporates themes from Body mass index, Physical therapy, Obstetrics, Prospective cohort study and Hormone replacement therapy.
Vitamin D and neurology is closely connected to Gastroenterology in his research, which is encompassed under the umbrella topic of Cancer.
He most often published in these fields:
- Internal medicine (76.49%)
- Breast cancer (61.27%)
- Oncology (38.15%)
What were the highlights of his more recent work (between 2016-2021)?
- Internal medicine (76.49%)
- Women's Health Initiative (36.42%)
- Breast cancer (61.27%)
In recent papers he was focusing on the following fields of study:
Rowan T. Chlebowski mainly investigates Internal medicine, Women's Health Initiative, Breast cancer, Hazard ratio and Oncology.
As part of his studies on Internal medicine, Rowan T. Chlebowski often connects relevant areas like Gynecology.
The study incorporates disciplines such as Incidence, Medroxyprogesterone acetate, Randomized controlled trial, Confidence interval and Hormone therapy in addition to Women's Health Initiative.
As a part of the same scientific study, Rowan T. Chlebowski usually deals with the Breast cancer, concentrating on Metabolic syndrome and frequently concerns with Triple-negative breast cancer.
His Hazard ratio study also includes
- Proportional hazards model, which have a strong connection to Confounding and Stage,
- Mortality rate which connect with Clinical trial.
His biological study spans a wide range of topics, including Odds ratio, Endocrine therapy, National Death Index and MEDLINE.
Between 2016 and 2021, his most popular works were:
- Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes (257 citations)
- Menopausal Hormone Therapy and Long-term All-Cause and Cause-Specific Mortality: The Women’s Health Initiative Randomized Trials (225 citations)
- Menopausal Hormone Therapy and Long-term All-Cause and Cause-Specific Mortality: The Women’s Health Initiative Randomized Trials (225 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Cancer
- Breast cancer
His primary scientific interests are in Internal medicine, Women's Health Initiative, Breast cancer, Hazard ratio and Proportional hazards model.
His research in Internal medicine intersects with topics in Gynecology and Oncology.
His Gynecology study combines topics in areas such as Cancer treatment and Cohort.
Rowan T. Chlebowski interconnects Breast cancer mortality, Medroxyprogesterone acetate, Mortality rate and Lower risk, Confidence interval in the investigation of issues within Women's Health Initiative.
The various areas that Rowan T. Chlebowski examines in his Medroxyprogesterone acetate study include Hormone therapy, Placebo and Hormone replacement therapy.
In general Breast cancer, his work in Aromatase is often linked to Risk assessment linking many areas of study.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
